Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 14/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | PTGES | O14684 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.55 |
| ▸ | LOX | P28300 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17833493 | 0.86 | ALOX5 (0.71) | ALOX5 | |
| SCHEMBL13696703 | 0.83 | ALOX5 (1.00) | ALOX5CYP1A2LMNAPTGS2 | |
| SCHEMBL9443921 | 0.83 | ALOX5 (1.00) | ALOX5CYP1A2LMNAPTGS2 | |
| Potassium SCHEMBL9443933 | 0.82 | ALOX5 (0.97) | ALOX5CYP1A2LMNAPTGS2 | |
| SCHEMBL9476877 | 0.81 | MMP9 (0.55) | ALOX5CYP1A2 | |
| SCHEMBL9473489 | 0.80 | ALOX5 (0.80) | ALOX5 | |
| SCHEMBL13524545 | 0.79 | ALOX5 (1.00) | ALOX5 | |
| SCHEMBL9374197 | 0.78 | ALOX5 (0.70) | ALOX5 | |
| SCHEMBL9475050 | 0.77 | ALOX5 (0.80) | ALOX5PTGS2 | |
| SCHEMBL9475006 | 0.76 | ALOX5 (0.76) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5185363-A | Administering for treatment of inflammatory diseases | ABBOTT LABORATORIES (US) | 1993-02-09 | — | — | US | disclosed |
| EP-0292699-A2 | Urea based lipoxygenase inhibiting compounds | ABBOTT LABORATORIES (US) | 1988-11-30 | — | — | EP | disclosed |